Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fianlimab + cemiplimab versus pembrolizumab after complete resection of high-risk melanoma
MOH_2023-04-03_012499Phase 3Not yet recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of fianlimab, cemiplimab and pembrolizumab in melanoma (3 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Recurrence prevention or delay. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on MOH_2023-04-03_012499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-04-03_012499.